| Drug General Information |
| Drug ID |
D0N4WB
|
| Former ID |
DNC004415
|
| Drug Name |
SB-415286
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H10ClN3O5
|
| InChI |
InChI=1S/C16H10ClN3O5/c17-10-7-8(5-6-12(10)21)18-14-13(15(22)19-16(14)23)9-3-1-2-4-11(9)20(24)25/h1-7,21H,(H2,18,19,22,23)
|
| InChIKey |
PQCXVIPXISBFPN-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
6173380, 8387211, 11109050, 11111800, 11114154, 11121581, 11122061, 11362650, 11365212, 11367774, 11370571, 11370572, 11373375, 11375936, 14828233, 17405044, 24278412, 26752224, 35496324, 47498109, 47498110, 47719265, 48317018, 49674511, 50069834, 50104914, 50104915, 53777587, 53789039, 56463775, 57356843, 71745855, 78669802, 85231226, 85788271, 90341705, 91722320, 92303814, 92309932, 99300846, 99302364, 103336904, 104022026, 112770517, 121264554, 121361147, 124659173, 124801122, 124881441, 124881442
|
| Target and Pathway |
| Target(s) |
Glycogen synthase kinase-3 beta |
Target Info |
Inhibitor |
[2]
|
|---|
| Ribosomal protein S6 kinase |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Chemokine signaling pathway
|
|
Cell cycle
|
|
PI3K-Akt signaling pathway
|
|
Wnt signaling pathway
|
|
Hedgehog signaling pathway
|
|
Axon guidance
|
|
Hippo signaling pathway
|
|
Focal adhesion
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Dopaminergic synapse
|
|
Insulin signaling pathway
|
|
Melanogenesis
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Alzheimer's disease
|
|
Hepatitis C
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Endometrial cancer
|
|
Prostate cancer
|
|
Basal cell carcinomahsa04012:ErbB signaling pathway
|
|
HIF-1 signaling pathway
|
|
mTOR signaling pathway
|
|
AMPK signaling pathway
|
|
TGF-beta signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Proteoglycans in cancer
|
|
Acute myeloid leukemia
|
|
Choline metabolism in cancer
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
|
Angiogenesis
|
|
Cadherin signaling pathway
|
|
Hedgehog signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
Wnt signaling pathway
|
|
Ras Pathway
|
|
CCKR signaling map STP00032:Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
p53 pathway by glucose deprivation
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Degradation of beta catenin
|
|
Reelin signaling pathway
|
|
Presenilin action in Notch and Wnt signaling
|
|
Integrin-linked kinase signaling
|
|
CDC42 signaling events
|
|
LKB1 signaling events
|
|
Canonical Wnt signaling pathway
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
Glucocorticoid receptor regulatory network
|
|
C-MYC pathway
|
|
Regulation of Androgen receptor activity
|
|
BMP receptor signaling
|
|
Hedgehog signaling events mediated by Gli proteins
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
Validated transcriptional targets of deltaNp63 isoforms
|
|
Aurora A signaling
|
|
Insulin-mediated glucose transport
|
|
Class I PI3K signaling events mediated by Akt
|
|
p53 pathway
|
|
Trk receptor signaling mediated by PI3K and PLC-gammainsulin_pathway:Insulin Pathway
|
|
IL4-mediated signaling events
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Regulation of Telomerase
|
|
mTOR signaling pathway
|
|
IGF1 pathway
|
|
IL2 signaling events mediated by PI3K
|
|
Integrins in angiogenesis
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
a6b1 and a6b4 Integrin signaling
|
|
TGF-beta receptor signaling
|
|
PathWhiz Pathway
|
Leucine Stimulation on Insulin Signaling
|
|
Reactome
|
Degradation of beta-catenin by the destruction complex
|
|
AKT phosphorylates targets in the cytosol
|
|
Regulation of HSF1-mediated heat shock response
|
|
CRMPs in Sema3A signaling
|
|
Disassembly of the destruction complex and recruitment of AXIN to the membrane
|
|
S33 mutants of beta-catenin aren't phosphorylated
|
|
S37 mutants of beta-catenin aren't phosphorylated
|
|
S45 mutants of beta-catenin aren't phosphorylated
|
|
T41 mutants of beta-catenin aren't phosphorylated
|
|
Degradation of GLI2 by the proteasome
|
|
Constitutive Signaling by AKT1 E17K in CancerR-HSA-166208:mTORC1-mediated signalling
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
Notch Signaling Pathway
|
|
Glycogen Metabolism
|
|
Insulin Signaling
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
IL-6 signaling pathway
|
|
Wnt Signaling Pathway Netpath
|
|
Copper homeostasis
|
|
Focal Adhesion
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Cardiac Hypertrophic Response
|
|
Degradation of beta-catenin by the destruction complex
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
Cardiac Progenitor Differentiation
|
|
BDNF signaling pathway
|
|
Corticotropin-releasing hormone
|
|
B Cell Receptor Signaling Pathway
|
|
IL17 signaling pathway
|
|
Neural Crest Differentiation
|
|
Alzheimers Disease
|
|
IL-7 Signaling Pathway
|
|
Regulation of Microtubule Cytoskeleton
|
|
TWEAK Signaling Pathway
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
Cell Cycle
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Androgen receptor signaling pathway
|
|
IL-5 Signaling PathwayWP673:ErbB Signaling Pathway
|
|
Interferon type I signaling pathways
|
|
G13 Signaling Pathway
|
|
IL-2 Signaling Pathway
|
|
Cytoplasmic Ribosomal Proteins
|
|
EGF/EGFR Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
Kit receptor signaling pathway
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Interleukin-11 Signaling Pathway
|
|
FSH signaling pathway
|
|
TSH signaling pathway
|
|
Signaling by Insulin receptor
|
|
TOR Signaling
|
|
AMPK Signaling
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8019). |
|---|
| REF 2 | Eur J Med Chem. 2009 Jun;44(6):2361-71. Epub 2008 Sep 16.Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. |
|---|
| REF 3 | Bioorg Med Chem Lett. 2001 Mar 12;11(5):635-9.3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). |
|---|
